Home / Business and Economy / Dr Reddy's Semaglutide: Canada Launch Nears Amid Global Ambitions
Dr Reddy's Semaglutide: Canada Launch Nears Amid Global Ambitions
18 Feb
Summary
- Dr Reddy's anticipates near regulatory approval for semaglutide in Canada.
- The company sees Canada as an early market opportunity before competition grows.
- Dr Reddy's focuses on global partnerships, biosimilars, and acquisitions for growth.
Dr Reddy's Laboratories is on the verge of regulatory approval for its generic semaglutide in Canada, with Co-Chairman and Managing Director G.V. Prasad indicating a potential launch as early as May 2026. Prasad stated that the company is responding to limited regulatory queries and anticipates a smooth approval process, positioning Canada as a crucial early market to capitalize on a window of opportunity before increased competition. Following this, Dr Reddy's plans to launch semaglutide in various global markets, contingent on patent rights and securing necessary approvals.
The company's broader growth strategy involves strengthening partnerships with global innovators to expand patient access to products. This approach is complemented by a focus on expanding its biosimilars pipeline, with potential significant contributions expected from FY27-FY28 onwards. Dr Reddy's is also selectively pursuing acquisitions, particularly in branded generics for India and emerging markets, and exploring opportunities in the global consumer health sector.
